These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29467925)

  • 1. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
    Boisen MK; Holst CB; Consalvo N; Chinot OL; Johansen JS
    Oncotarget; 2018 Jan; 9(6):6752-6762. PubMed ID: 29467925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
    J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
    Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
    Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
    Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
    Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.
    Jiguet-Jiglaire C; Boissonneau S; Denicolai E; Hein V; Lasseur R; Garcia J; Romain S; Appay R; Graillon T; Mason W; Carpentier AF; Brandes AA; Ouafik L'; Wick W; Baaziz A; Gigan JP; Argüello RJ; Figarella-Branger D; Chinot O; Tabouret E
    Acta Neuropathol Commun; 2022 Jan; 10(1):1. PubMed ID: 34980260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
    Weller J; Zeyen T; Schäfer N; Schaub C; Potthoff AL; Steinbach JP; Hau P; Seidel C; Goldbrunner R; Tabatabai G; Vatter H; Tzaridis T; Schneider M; Herrlinger U
    J Neurooncol; 2023 Sep; 164(3):749-755. PubMed ID: 37787906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
    Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T
    Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
    Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
    J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies.
    Bian B; Li L; Yang J; Liu Y; Xie G; Zheng Y; Zeng L; Zeng J; Shen L
    Cancer Cell Int; 2019; 19():259. PubMed ID: 31624472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.
    Qin G; Li X; Chen Z; Liao G; Su Y; Chen Y; Zhang W
    Mol Neurobiol; 2017 Jul; 54(5):3264-3270. PubMed ID: 27090900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.
    Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P
    Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
    van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
    Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.
    Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J
    J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40.
    Holst CB; Christensen IJ; Skjøth-Rasmussen J; Hamerlik P; Poulsen HS; Johansen JS
    Front Oncol; 2020; 10():478. PubMed ID: 32363159
    [No Abstract]   [Full Text] [Related]  

  • 19. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?
    Brandes AA; Mason W; Pichler J; Nowak AK; Gil M; Saran F; Revil C; Lutiger B; Carpentier AF
    Future Oncol; 2014 May; 10(7):1137-45. PubMed ID: 24947255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.